SARS-CoV-2 breath tests implementation for the rapid COVID-19 surveillance: a game changer? A review of existing data

Alejandro Vallejo Degaudenzi¹
Daniela M. Hernández¹
Daniela Hidalgo¹
Elisa Contreras¹
María L. Ceballos¹
Mariel Polanco¹
Máximo Reynoso¹
Nicole Hernández²
Camila Marranzini¹
Robert Paulino-Ramirez¹

ABSTRACT

The Coronavirus Disease 2019 (COVID-19) pandemic has been spread across the globe for almost a year, causing economic, social, and psychological impacts with yet unknown dimensions. In emerging and reemerging pathogen surveillance and detection, polymerase chain reaction (PCR) is a classic laboratory technique that has been widely used for the amplification and identification of nucleic acids. Analysis of volatile organic compounds in breath has been long reviewed as a potential diagnostics tool for many diseases. The overall specificity for SARS-CoV-2 of these methods was calculated and revealed a low value for reliable detection. Breath tests are not a sufficiently evidence-based approach for rapid screening and to “secure” or creating “sanctuary” regions for touristic purposes. Therefore, policymakers must cautiously point out the importance of further evaluation and structured studies confronting gold-standards with new devices. This review aims to evaluate the possible potential of this novel diagnosis test within a public health perspective considering its implementation on a resource limited environment.

BACKGROUND

The Coronavirus Disease 2019 (COVID-19) pandemic has been spread across the globe for almost a year, causing economic, social, and psychological impact [1] with yet unknown dimensions [2]. The World Health Organization’s Chief director, as early as March 2020, called for a simple but very urgent message to test, test, and test, pointing on the importance of large-scale testing and contact tracing as a significant effort to limit the impact of the pandemic. Nevertheless, this call is of most significant importance when it relies on diagnostic tests that can offer a rapid and conclusive detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

However, in countries with limited resources, testing all populations and especially vulnerability communities, or most-at-risk populations is a cumbersome venture; reinforcing the importance of accurate isolation, early management- if symptoms are present-, and precise geographic interventions when hotspots are localized, all of this cemented by the appropriate testing capacities [4,5].

Therefore, the development of effective and validated methods for SARS-CoV-2 detection has been one of the main objectives of the scientific community...
since the emergence and completed sequenced virus. [6] In emerging and reemerging pathogen surveillance and detection, PCR is a classic laboratory technique that has been widely used for the amplification and identification of nucleic acids [6]. Considering that this technique’s basis is already well established, the quantitative reverse transcription-polymerase chain reaction (RT-qPCR) has been applied for the molecular detection of SARS-CoV-2 even from biological tissues. It is currently the most robust in terms of the effective diagnosis of the disease [7-9].

Even though the RT-PCR technique presents high specificity, sensitivity, and reproducibility rates and allows a high number of tests performed in relatively short time intervals [10], it is also limited by the high costs of the appliances and equipment necessary PCR. Without mentioning operational errors during sample processing and the unavailability of adequate storage systems for reagents [11]. In search of new, fast, and low-price detection methods, a Point-of-Care (PoC) approach is considered. PoC diagnostic tests offer immediate results without requiring specialized technical personnel or a diagnostic laboratory infrastructure [12].

PoC test types include the so-called “rapid test” or serology test. They consist of simple immunochromatographic examinations that detect the presence of IgM and IgG antibodies in response to SARS-CoV-2 infection in serum, plasma, or blood samples. IgM antibodies begin to be detectable in blood one week after the infection begins. In contrast, IgG antibodies appear in the late stage of the infection, which generally occurs after the second week and persists over time [14].

Serologic tests are based on the detection of antibodies against a specific targeted protein. Antibodies to the nucleocapsid protein are the most sensitive target for serological diagnosis of infection with SARS-CoV-2 [15]. Antibodies against the spike protein of SARS-CoV-2, the target of neutralizing antibody, emerge later than those against the nucleocapsid protein [16]. Despite this findings, further studies are needed to understand antibody dynamics in persons infected with SARS-CoV-2 to determine the most sensitive and specific antibody assays and to use these antibody-based tests to determine seroprevalence in different populations.

When it comes to this type of test's limitations, detecting specific immunoglobulins to a particular antigen makes it challenging to ascertain when they appear in blood samples so that a false negative diagnosis could be given [17]. Likewise, due to the SARS-CoV-2 profile, virus-specific IgG/IgM tests should not be considered a confirmatory diagnosis but as a complementary technique to molecular genetic analysis such as RT-qPCR [17,18]. In an earlier study that surveyed a total of 12,897 participants between April and June of 2020 in 10 provinces of the Dominican Republic, emerging hotspots yielded a positivity for all participants of anti–SARS-CoV-2 IgM of only 3.8% and IgG of 5.4% [19].

Recently another PoC test that attempts to diagnose COVID-19 using antigen (Ag) detection has been tested. These assays are currently in use based on a nitrocellulose membrane technology and nanoparticles based on colloidal gold sensitized with monoclonal antibodies directed against highly conserved SARS-CoV-2 antigens [20]. Some authors conclude that the assay is used to diagnose the disease within a few days after symptom onset when the upper respiratory tract's virus load is at its peak [21,22]. Understanding advantages and limitations of using Ag tests in different populations across a prevalence range will allow the tests to be deployed simultaneously with others to improve the COVID-19 response.

Given the current availability of different types of COVID-19 tests, countries are still struggling to meet crucial testing demands for patient management and surveillance. Molecular tests and Rapid Tests have different but complimentary roles in the pandemic response.

**SARS-CoV-2 breath tests**

A search of the PubMed electronic database was undertaken using the search terms “novel coronavirus”, “COVID-19”, “nCoV”, “Breath-Test”, “Breath”, “Rapid Test” and “SARS-CoV-2” in various permutations and combinations. The literature search was performed with articles which were accepted before April of the year 2021.

Analysis of volatile organic compounds (VOCs) present in breath has been long reviewed as a potential diagnostics tool for many diseases [23-26]. Chen et al. reported possible breath-borne VOC biomarkers
for SARS-CoV-2. Infected patients show to possess statistically significantly higher levels of ethyl butyrate (29.13–95.67) (95% CI, N = 10) than healthy controls (16–24.3) (95% CI, N = 12). Also, statistically, significantly lower levels of isopropanol (RI: 920.7; Dt: 1.2224) than healthy controls are considered as an infection proxy [27]. These two VOCs suggest that this methodology represents a "game-changer" in rapid viral detection as proposed. Mechanics of breath analysis based on gas chromatography (GC) coupled with mass spectrometry (MS) or ion mobility spectrometry (IMS) [29], as well as other slightly unorthodox yet interesting approaches like scent detection of VOCs specific to SARS-CoV-2 with trained dogs. [30] In the first case, this study implies a particular limitation with the use of GC-IMS, such as environmental contamination, which ultimately results in an incapacity to resolve signals because of the charge transfer [31].

According to Ruszkiewicz et al, for GC-IMS to be a more feasible option, there would have to be a significant development in an ionization source. Since this device requires photo-ionization mechanisms and atmospheric pressure ionization charge transfer for it to work correctly, there is a lot more buildup needed when it comes to the source for the technique to function adequately [29].

Another recent method described by Shan et al. consists of a portable device that evaluates the variation in electrical conductivity, which occurs due to the interaction of SARS-CoV-2 VOCs with specific ligands. The device consists of two parts: an inorganic part composed of gold nanoparticles and an organic part. Organic ligands are found, thus creating a useful matrix that reacts to VOCs [32] When performing the test on an infected individual, the VOCs will diffuse or remain on the matrix’s surface, reacting with the organic part and with the functional groups found on the inorganic compounds, altering the volume, be it inflation or contraction. This volume alteration results in an increase or decrease in the electrical conductivity detected by sensors [33] Devices would assess these VOCs’ presence, facilitating to quickly detect SARS-CoV-2 and discriminate it from others that might produce similar symptoms. VOCs are mostly present in a breath when the individual is in the first weeks of their infection, which could allow the early identification of COVID-19, thus diminishing the possibility of subsequent infections and improving the chances of rapid recovery individual [33].

To test the effectiveness of the technique, 140 patients from Wuhan took part in testing experiments. Three groups were considered: individuals infected with SARS-CoV-2, individuals with no signs of infection, and individuals that possessed other lung infections. The results showed that the test is close to PCR’s exact detection percentages, which correspond to 82-98%. Regarding sensitivity, the values ranged between 83 and 90%, which exceeded the average of current rapid detection tests for SARS-CoV-2 [23]. These results suggest the portable 2-dimensional gas chromatography (p2d-GC) device is indeed suited for SARS-CoV-2 detection, which is still a fundamental shortcoming in the specificity values. The overall specificity for SARS-CoV-2 of this method was a calculated 69% [23], which is a low value for reliable detection.

It is important to note that, since these results can only be attributed to a pre-diagnosed population in Wuhan, China, these sensitivity, and specificity values cannot be taken as absolute to determine the average that this test would consistently present accurately. Due to the findings of sensitivity and specificity, some elements of internal and external validity remain answered.

Another two independent observational prevalence studies at Edinburgh, UK, and Dortmund, Germany were developed to evaluate the feasibility of using breath-analysis to differentiate SARS-COV-2 infection from other respiratory diseases [29]. These studies aimed to trial point-of-care testing using self-contained gas chromatography-ion mobility spectrometry (GC-IMS) breath-analyzers in two hospitals and evaluate the breath biochemistry for possible markers of SARS-COV-2. The following VOCs were found to be potentially discriminating for SARS-COV-2: ethanol, octanal, acetone, butanone, methanol, heptanal, and an unknown compound named feature 144.

From a total of 90 participants, 25 in Edinburgh and 65 in Dortmund, the VOC-based diagnosis agreed with the RT-q-PCR diagnosis using a Principal Component Analysis (PCA) multi-variate analysis. The Dortmund PCA stratification model had 90% sensitivity and 80% specificity and an area under the receiver operator characteristic (AUROC) of 0.91.
for distinguishing SARS-COV-2 patients from other patients. Meanwhile, the resultant PCA stratification model in Edinburgh had 82.4% sensitivity and 75% specificity with an AUROC of 0.87 for distinguishing SARS-COV-2 patients from other patients [29].

The compounds identified indicated that changes in breath biochemistry followed the same pattern in both studies with elevated ketone; aldehyde and feature 144 signals accompanied by a suppressed methanol signal were proved to be significant. These biomarkers are in concordance with a combination of extrapulmonary, metabolic, and gastrointestinal manifestations of COVID-19 within the body and airway inflammatory responses, such as ketosis [32], impaired gastrointestinal function [33], and inflammatory responses [35].

Suppose further investigations with several populations, using confirmatory analytical techniques such as gas chromatography-mass spectrometry (GC-MS/IMS), show to be reliable. In that case, these SARS-CoV-2 breath tests offers the possibility for rapid diagnosis of SARS-COV-2 in emergency rooms and primary care units that have the infrastructure and equipment for required for this analysis. The results of this studies are summarized in Table 1.

## CONCLUSIONS

When it comes to developing new diagnostic tests to meet public health demands in the face of the SARS-CoV-2 pandemic, technologies aimed at designing and generating fast and affordable tests. However, approving these tests for diagnostic use requires peer-reviewed studies that confirm their ability to offer a reliable result. Were these tests not subjected to rigorous research, the method in question would run the risk of yielding imprecise results that do not adequately reflect the epidemiological landscape, thus obstructing public health decision-making.

The number of studies available to date for the rapid detection method of SARS-CoV-2 in-breath is not sufficient to justify their immediate public use. It is necessary to carry out studies in different populations so that the specificity of the presented method increases compared to the standard RT-qPCR technique, which remains the preferred one for diagnosing SARS-CoV-2, despite its limitations.

Tests based on direct and indirect identification techniques of SARS-COV-2 are of high interest to the public health authorities. The SARS-CoV-2 breath test has characteristics that can facilitate its implementation since it makes implications of the viral presence in patients, and the costs would also be minimal. However, the rapid detection method of SARS-CoV-2 in breath has minimal references in peer review journals, representing a gap in its application knowledge.

Before having full confidence in this test and starting its commercialization, more studies with a robust scientific design were carried out to evaluate its precise detection capacity and the variability of the results in different geographical areas. Breath tests are not a sufficiently evidence-based approach for rapid screening and to “secure” or creating “sanctuary” regions for touristic purposes. Therefore, policymakers must cautiously take this, pointing to the importance of further evaluation and structured studies confronting gold-standards with new devices.

| Location     | Principle | Population studied | Selected groups                                                                 | Sensitivity (values ranged) | Specificity  | References |
|--------------|-----------|--------------------|---------------------------------------------------------------------------------|----------------------------|-------------|------------|
| Wuhan        | P2D-GC    | 140 patients       | Three groups were considered: individuals infected with SARS-CoV-2, individuals with no signs of infection, and individuals that possessed other lung infections. | 83-90 %                   | 69 %        | 23         |
| Edinburgh    | GC-IMS    | 25 patients        | Individuals infected with SARS-CoV-2                                           | 82.4 %                     | 75%         | 27         |
| Dortmund     | GC-IMS    | 65 patients        | Individuals infected with SARS-CoV-2                                           | 90 %                       | 80%         | 27         |
Contributions

AVD and RPR conceived the manuscript and thoroughly revised the literature. AVD, DMH, DH, EC, MP, MR and CM revised the existing literature on SARS-CoV-2 tests and provide insights on technical characteristics. AVD and RPR drafted the revised version of the manuscript; and critically revised the manuscript for intellectual content and approved the final version. RPR is the guarantor of the paper.

REFERENCES

1. Mencía-Ripley A, Paulino-Ramírez R, Féliz-Matos L, Ruiz-Matuk CB, Sánchez-Vincitore LV. Psychological responses to the COVID-19 outbreak are related to trust in public institutions: Implications for management of emerging infectious diseases. IAJMH. 2021;4. http://dx.doi.org/10.31005/iajmh.v4i.164

2. Chakraborty I, Maity P. COVID-19 outbreak: Migration, effects on society, global environment, and prevention. Sci Total Environ. 2020;728(138882):138882. http://dx.doi.org/10.1016/j.scitotenv.2020.138882

3. WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 March 2020 [Internet]. Who.int. 20AD. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020

4. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–5. http://dx.doi.org/10.1038/s41591-020-0869-5

5. Corman VM, Landt O, Kaiser M, Mölenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045

6. Loeffelholz MJ, Tang Y-W. Laboratory diagnosis of emerging human coronavirus infections - state of the art. Emerg Microbes Infect. 2020;9(1):747–56. http://dx.doi.org/10.1080 / 22221751.2020.1745095

7. u F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020 Jul 28;71(15):793-798. http://dx.doi.org/10.1093/cid/ciaa345

8. Park GS, Ku K, Baek SH, Kim SJ, Kim SL, Kim BT, Maeng JS. Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). J Mol Diagn. 2020 Jun;22(6):729-735. http://dx.doi.org/10.1016/j. jmoldiag.2020.03.006

9 Afzal A. Molecular diagnostic technologies for COVID-19: Limitations and challenges. J Adv Res. 2020;26:149–59.

10. Jalali M, Zaborowska J, Jalali M. The polymerase chain reaction. In: Basic Science Methods for Clinical Researchers. Elsevier; 2017.

11. Nguyen T, Zoëga Andreasen S, Wolff A, Duong Bang D. From lab on a chip to the point of care devices: The role of open-source microcontrollers. Micromachines. 2018; 9 (8): 403. http://dx.doi.org/1010.3390/mi9080403

12. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report. J Infect. 2020;81(1):147–78.

13. Vizcaino-Carruyo JC, Tangarife-Castaño VJ, Campuzano-Zuluaga G, Toro-Montoya A. COVID-19 anticuerpos IgM/IgG por ensayo inmunocromatográfico (prueba rápida). Med y Lab. 2020;24(3):255–7.

14. Aguilar Ramírez P, Enriquez Valencia Y, Quiroz Carrillo C, Valencia Ayala E, de León Delgado J, Pareja Cruz A. Pruebas diagnósticas para la COVID-19: la importancia del antes y el despúes. Horiz méd. 2020;20(2).

15. Dong X, Cao Y-Y, Lu X-X, Zhang J-J, Du H, Yan Y-Q, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699–709.

16. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. http://dx.doi.org/10.1093/cid/ciaa344

17. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020 Jul 28;71(15):778-785. http://dx.doi.org/10.1093/cid/ciaa310
18. Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso A-M, et al. Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs. J Clin Microbiol. 2020;58(8). http://dx.doi.org/10.1093/cid

19. Paulino-Ramirez R, Báez AA, Vallejo Degaudenzi A, Tapia L. Seroprevalence of specific antibodies against SARS-CoV-2 from hotspot communities in the Dominican Republic. Am J Trop Med Hyg. 2020;103(6):2343–6. http://dx.doi.org/10.1093/cid

20. Mertens P, De Vos N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, et al. Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context. Front Med. 2020;7:225. http://dx.doi.org/10.1093/cid

21. Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J Clin Virol. 2020;129(104500). http://dx.doi.org/10.1093/cid

22. Zalzala HH. Diagnosis of COVID-19: facts and challenges. New Microbes New Infect. 2020;38(100761).

23. Zhou M, Sharma R, Zhu H, Li Z, Li J, Wang S, et al. Rapid breath analysis for acute respiratory distress syndrome diagnostics using a portable two-dimensional gas chromatography device. Anal Bioanal Chem. 2019;411(24):6435–47.

24. Moor CC, Oppenheimer JC, Nakshbandi G, Aerts JGJV, Brinkman P, Maitland-van der Zee A-H, et al. Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. Eur Respir J. 2021;57(1):2002042.

25. Van Oort PMP, Nijsen T, Weda H, Knobel H, Dark P, Felton T, et al. BreathDx - molecular analysis of exhaled breath as a diagnostic test for ventilator-associated pneumonia: protocol for a European multicentre observational study. BMC Pulm Med. 2017;17(1):1.

26. Van Keulen Ke, Jansen ME, Schrauwen RWM, Kolkman JJ, Siersema PD. Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer. Aliment Pharmacol Ther. 2020;51(3):334–46.

27. Chen H, Qi X, Ma J, Zhang C, Feng H, Yao M. Breath-borne VOC Biomarkers for COVID-19. medRxiv. 2020. Available from: http://dx.doi.org/10.1101/2020.06.21.20136523

28. Walker HJ, Burrell MM. Could breath analysis by MS could be a solution to rapid, non-invasive testing for COVID-19? Bioanalysis. 2020;12(17):1213–7.

29. Ruszkiewicz DM, Sanders D, O’Brien R, Hempel F, Reed MJ, Riepe AC, et al. Diagnosis of COVID-19 by analysis of breath with gas chromatography-ion mobility spectrometry - a feasibility study. EClinicalMedicine. 2020;29(10069).

30. Jendrny P, Schulz C, Twele F, Meller S, von Köckritz-Blickwede M, Osterhaus ADME, et al. Scent dog identification of samples from COVID-19 patients - a pilot study. BMC Infect Dis. 2020;20(1):536.

31. Shan B, Broza YY, Li W, Wang Y, Wu S, Liu Z, et al. Multiplexed nanomaterial-based sensor array for detection of COVID-19 in exhaled breath. ACS Nano. 2020;14(9):12125–32.

32. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020;22(10):1935–41.

33. Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, Panaccione R, et al. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res. 2012;11(6):3344–57. http://dx.doi.org/10.1021/pr300139q.

34. Ratcliffe N, Wieczorek T, Drabińska N, Gould O, Osborne A, De Lacy Costello B. A mechanistic study and review of volatile products from peroxidation of unsaturated fatty acids: an aid to understanding the origins of volatile organic compounds from the human body. J Breath Res. 2020;14(3):1-5. http://dx.doi.org/10.1088/1752-7163/ab7f9d